跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How AI Predicts Drug Failure Before Human Trials

1Why Predicting Drug Failure Matters2What AI Learns From: The Data Behind Predictions3How AI Turns Data Into a Failure Prediction4Judging Whether a Prediction Can Be Trusted5How Predictions Are Used in Real Drug Development
Judging Whether a Prediction Can Be Trusted

When the Pattern Stops Applying

3 / 4
The example is worth walking through slowly. A model built mostly from oral small-molecule drugs for metabolic disease has learned what failure tends to look like in that territory. Now hand it a biologic for an autoimmune condition. The molecular feature it treats as a warning sign may not even exist in the same form, and the comparison group of similar past drugs may be only a handful of entries. Yet the model still returns a number, and that number looks exactly as confident as one backed by thousands of examples. Nothing in the output tells you the model has left its territory. That is the point: reliability is local, and checking whether a candidate sits inside the training territory is a job for a person, because the score itself will never flag the problem.
0:00 / 0:00

A model's reliability is local to the chemical and biological territory of its training drugs. Performance on a familiar class does not transfer to a genuinely new one, and the model will not signal that it has left its territory.

Two reasons the pattern breaks down

The same measured property can carry a different meaning in a new chemical family, so a feature the model treats as a warning sign may be neutral or even favorable there. Separately, a new class is usually underrepresented in the history, leaving too few comparable past drugs for a stable estimate. Both problems produce a normal-looking score rather than an obvious error.

A concrete illustration

Suppose a model was built mostly from oral small-molecule drugs for metabolic disease, where a certain molecular feature often accompanied liver-related failure. A biologic for an autoimmune condition sits far outside that territory: the feature may not exist in the same form, and the comparison group of similar past drugs may be a handful of entries. The model still returns a number, and that number looks no different from a well-supported one — which is exactly why the territory has to be checked by a person, not inferred from the score.

上一页3 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion